We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Markers Predict Disease Severity for RSV Infections

By LabMedica International staff writers
Posted on 26 Nov 2013
Profound systemic dysregulation of the immune response induced by respiratory syncytial virus (RSV) infection in young children indicates that molecular markers might be able to predict disease severity.

RSV is the leading cause of viral lower respiratory tract infection (LRTI) and hospitalization in infants and because of the incomplete understanding of the disease pathogenesis, there is no licensed vaccine, and treatment remains symptomatic.

Scientists at the Nationwide Children's Hospital (Columbus, OH, USA) and their colleagues examined the global gene expression patterns in blood samples from four different cohorts of children who were hospitalized with lower respiratory tract infections. More...
Whole blood ribonucleic acid (RNA) was processed and hybridized into Human WG-6 v3 or Human HT-12 v4 beadchips and scanned on the Beadstation 500 system (Illumina; San Diego, CA, USA).

They found that children who are ill with RSV infections have a characteristic gene expression pattern that is different, not only from healthy children but also from children infected with either influenza virus or human rhinovirus, two other common causes of lower respiratory tract disease. This pattern, which the scientists called the RSV biosignature, could reliably identify children with RSV infections in different settings. From it, they derived a genomic severity score that correlated with clinical indices of disease severity, with length of hospitalization, and the need for supplemental oxygen.

The RSV biosignature also provided insights into the status of the immune system in the sick children. RSV infection was associated with elevated levels of some inflammation genes as well as suppression of nonspecific immune system genes and reduced expression of specific B and T cell genes. This was particularly evident in infants under six months of age.

The authors concluded that blood RNA profiles of infants with RSV lower respiratory tract infections allow specific diagnosis, better understanding of disease pathogenesis, and assessment of disease severity, and they add, their study opens new avenues for biomarker discovery and identification of potential therapeutic or preventive targets. The study was published on November 12, 2013, in the journal Public Library of Science Medicine.

Related Links:

Nationwide Children's Hospital
Illumina 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.